The Food and Drug Administration (FDA) of United States announced a new drug to treat chronic myelofibrosis. The medicine is Inrebic, also called Fedratinib. This drug can be used to treat both stages of myelofibrosis; primary and secondary. This is the only the second approved drugs from FDA that can be used to treat myelofibrosis.
The approval was received after scientists performed a clinical trial on the medicine. 289 myelofibrosis patients participated in this test. They were randomly given 400-500mg of the Inrebic medicine. There was couple of options to have this potent; orally or placebo. Participants who were given 400mg dose, out of 96 patients, 35 witnessed a reduction in the spleen volume; there was approximately 35% reduction in the spleen. This reduction took place gradually from the start date of the medicine till the 24th week. The measurement was done using computed tomography scan or magnetic resonance imaging. 36 patients experienced a reduction in the symptoms related to myelofibrosis by 50%. These indications generally included sweating at night, feeling full just half through a meal, pain in the left ribs, abdominal issues, bone or muscle ache and itching.
The Inrebic medicine box warns the users of the critical issues which can occur if not consumed safely or within the recommended dose. Physicians are advised to check the levels of Thiamine of the patient before and during the course of this medication. At any point of time if the doctor feels that Inrebic consumption is leading to encephalopathy, the medication should be discontinued. The other tests which should be done at regular intervals when having this medicine are presence of toxins in the gastrointestinal part.
The known side effects of taking this medicine are vomiting, diarrhea, muscle spasms and nausea. Some patients might even face critical health issues like anemia and thrombocytopenia.